Leucinal | CAS#82473-52-7 | aminopeptidase inhibitor

MedKoo Cat#: 597414 | Name: Leucinal

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Leucinal is a potent and reversible inhibitor of calpain, a calcium-dependent cysteine protease involved in various cellular processes including apoptosis, cell motility, and signal transduction. Leucinal exhibits IC₅₀ values in the low micromolar range for calpain I and II (typically around 1–10 µM), demonstrating selectivity over other cysteine proteases such as cathepsins. Studies have shown that Leucinal can inhibit calpain-mediated proteolysis in neuronal and muscle cells, reducing degradation of cytoskeletal proteins like spectrin. In cell-based assays, Leucinal has been used to attenuate calpain-related pathways implicated in neurodegenerative diseases, ischemia, and cancer metastasis, highlighting its potential as a pharmacological tool for dissecting calpain-dependent mechanisms.

Chemical Structure

Leucinal

CAS#82473-52-7

Theoretical Analysis

MedKoo Cat#: 597414

Name: Leucinal

CAS#: 82473-52-7

Chemical Formula: C6H13NO

Exact Mass: 115.0997

Molecular Weight: 115.17

Elemental Analysis: C, 62.57; H, 11.38; N, 12.16; O, 13.89

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Leucinal; L-Leucinal; N-formyl-leucyl-leucyl-phenylalanine; L-leucyl-L-leucinal;

IUPAC/Chemical Name

(S)-2-amino-4-methylpentanal

InChi Key

ZOFRRNUENOHELM-LURJTMIESA-N

InChi Code

InChI=1S/C6H13NO/c1-5(2)3-6(7)4-8/h4-6H,3,7H2,1-2H3/t6-/m0/s1

SMILES Code

CC(C)C[C@H](N)C=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 115.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Davis KR, Hernandez DE, Wolfenden R. Leucinal inhibits brain aminopeptidase activity and potentiates analgesia induced by leu-enkephalen. Pharmacol Biochem Behav. 1983 Nov;19(5):791-4. PubMed PMID: 6647514. 2: Sträter N, Lipscomb WN. Two-metal ion mechanism of bovine lens leucine aminopeptidase: active site solvent structure and binding mode of L-leucinal, a gem-diolate transition state analogue, by X-ray crystallography. Biochemistry. 1995 Nov 14;34(45):14792-800. PubMed PMID: 7578088. 3: Princiotta MF, Schubert U, Chen W, Bennink JR, Myung J, Crews CM, Yewdell JW. Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):513-8. Epub 2001 Jan 9. PubMed PMID: 11149939; PubMed Central PMCID: PMC14618. 4: Ito H, Watanabe M, Kim YT, Takahashi K. Inhibition of rat liver cathepsins B and L by the peptide aldehyde benzyloxycarbonyl-leucyl-leucyl-leucinal and its analogues. J Enzyme Inhib Med Chem. 2009 Feb;24(1):279-86. doi: 10.1080/14756360802166921 . PubMed PMID: 18830882. 5: Inoue J, Nakamura M, Cui YS, Sakai Y, Sakai O, Hill JR, Wang KK, Yuen PW. Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor. J Med Chem. 2003 Feb 27;46(5):868-71. PubMed PMID: 12593666. 6: Beveridge RE, Batey RA. An organotrifluoroborate-based convergent total synthesis of the potent cancer cell growth inhibitory depsipeptides kitastatin and respirantin. Org Lett. 2014 May 2;16(9):2322-5. doi: 10.1021/ol500484f. Epub 2014 Apr 14. PubMed PMID: 24730576. 7: Zhang Y, Yang B, Zhao J, Li X, Zhang L, Zhai Z. Proteasome Inhibitor Carbobenzoxy-L-Leucyl-L-Leucyl-L-Leucinal (MG132) Enhances Therapeutic Effect of Paclitaxel on Breast Cancer by Inhibiting Nuclear Factor (NF)-κB Signaling. Med Sci Monit. 2018 Jan 15;24:294-304. PubMed PMID: 29332931; PubMed Central PMCID: PMC5779800. 8: Andersson L, Isley TC, Wolfenden R. alpha-aminoaldehydes: transition state analogue inhibitors of leucine aminopeptidase. Biochemistry. 1982 Aug 17;21(17):4177-80. PubMed PMID: 7126535. 9: Steensma DP, Ebert BL. Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion. Blood. 2013 May 23;121(21):4428. doi: 10.1182/blood-2013-03-493809. PubMed PMID: 23704049. 10: Han YH, Moon HJ, You BR, Park WH. The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 2009 Jul;22(1):215-21. PubMed PMID: 19513526. 11: Zhu W, Liu J, Nie J, Sheng W, Cao H, Shen W, Dong A, Zhou J, Jiao Y, Zhang S, Cao J. MG132 enhances the radiosensitivity of lung cancer cells in vitro and in vivo. Oncol Rep. 2015 Oct;34(4):2083-9. doi: 10.3892/or.2015.4169. Epub 2015 Aug 4. PubMed PMID: 26238156. 12: Ma Y, Xu B, Fang Y, Yang Z, Cui J, Zhang L, Zhang L. Synthesis and SAR study of novel peptide aldehydes as inhibitors of 20S proteasome. Molecules. 2011 Sep 5;16(9):7551-64. doi: 10.3390/molecules16097551. PubMed PMID: 21894088. 13: Fan X, Chai L, Zhang H, Wang Y, Zhang B, Gao X. Borneol Depresses P-Glycoprotein Function by a NF-κB Signaling Mediated Mechanism in a Blood Brain Barrier in Vitro Model. Int J Mol Sci. 2015 Nov 18;16(11):27576-88. doi: 10.3390/ijms161126051. PubMed PMID: 26593909; PubMed Central PMCID: PMC4661909. 14: Noack M, Richter-Landsberg C. Activation of autophagy by rapamycin does not protect oligodendrocytes against protein aggregate formation and cell death induced by proteasomal inhibition. J Mol Neurosci. 2015 Jan;55(1):99-108. doi: 10.1007/s12031-014-0380-x. Epub 2014 Jul 29. PubMed PMID: 25069858. 15: Jeong JB, Lee J, Lee SH. TCF4 Is a Molecular Target of Resveratrol in the Prevention of Colorectal Cancer. Int J Mol Sci. 2015 May 7;16(5):10411-25. doi: 10.3390/ijms160510411. PubMed PMID: 25961950; PubMed Central PMCID: PMC4463653. 16: Matsumoto Y, Miyamoto Y, Cabral H, Matsumoto Y, Nagasaka K, Nakagawa S, Yano T, Maeda D, Oda K, Kawana K, Nishiyama N, Kataoka K, Fujii T. Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating the proteasome inhibitor MG132. Cancer Sci. 2016 Jun;107(6):773-81. doi: 10.1111/cas.12926. Epub 2016 Apr 27. PubMed PMID: 26987571; PubMed Central PMCID: PMC4968607. 17: Chen H, Yang H, Pan L, Wang W, Liu X, Ren X, Liu Y, Liu W, Zhang Y, Jiang L, Li K, Zhang B, Wang LX. The molecular mechanisms of XBP-1 gene silencing on IRE1α-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress. Biomed Pharmacother. 2016 Feb;77:108-13. doi: 10.1016/j.biopha.2015.12.010. Epub 2015 Dec 29. PubMed PMID: 26796273. 18: Lee HW, Smith L, Pettit GR, Vinitsky A, Smith JB. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J Biol Chem. 1996 Aug 30;271(35):20973-6. PubMed PMID: 8702857. 19: Guo N, Peng Z, Zhang J. Proteasome Inhibitor MG132 Enhances Sensitivity to Cisplatin on Ovarian Carcinoma Cells In Vitro and In Vivo. Int J Gynecol Cancer. 2016 Jun;26(5):839-44. doi: 10.1097/IGC.0000000000000703. PubMed PMID: 27051056. 20: Macías-Vidal J, Girós M, Guerrero M, Gascón P, Serratosa J, Bachs O, Coll MJ. The proteasome inhibitor bortezomib reduced cholesterol accumulation in fibroblasts from Niemann-Pick type C patients carrying missense mutations. FEBS J. 2014 Oct;281(19):4450-66. doi: 10.1111/febs.12954. Epub 2014 Aug 21. PubMed PMID: 25131710.